Thus, a recent study showed in a group of patients with metastatic castration-resistent prostate cancer treated with docetaxel chemotherapy, those with ERG+ primary tumors have a two times increased risk of therapy resistance than those with ERG- tumors [367]. This evidence concerns the gene ERG and Familial prostate cancer.